Sign in

    Yuriy Slutskyy

    Senior Biotech Equity Research Associate at BMO Capital Markets

    Yuriy Slutskyy is a Senior Biotech Equity Research Associate at BMO Capital Markets, specializing in biotechnology sector research. He supports coverage of leading biotech companies, leveraging his advanced academic background (PhD, MBA) to provide data-driven analysis for institutional investors. Slutskyy began his current analyst career at BMO Capital Markets in 2024 and holds active FINRA registration under CRD# 7834182, demonstrating compliance with key industry regulatory standards. Prior to joining BMO, he developed significant experience in scientific and business research, underscoring his comprehensive credentials in both biotech and financial services.

    Yuriy Slutskyy's questions to Intellia Therapeutics (NTLA) leadership

    Yuriy Slutskyy's questions to Intellia Therapeutics (NTLA) leadership • Q2 2025

    Question

    Representing Kostas Biliouris at BMO Capital Markets, Yuriy Slutskyy asked for the company's latest thoughts on the potential drivers of Grade 4 liver function test (LFT) changes observed after Nexi treatment.

    Answer

    President and CEO John Leonard corrected that the event was a Grade 1 (mild) elevation by drug-induced liver injury scoring, not Grade 4. He reported the patient was asymptomatic, has returned to baseline, and remains in the study. He stated the company's belief is that the event is unlikely to be directly related to the LNP delivery system and the cause remains under investigation.

    Ask Fintool Equity Research AI